Lowest Price Guaranteed
Slides
207
Last Updated
July 2026
View Count
11999
The global peptide receptor radionuclide therapy market is expected to grow from USD 2.7 billion in 2025 to USD 30.1 billion by 2035, representing a CAGR of 27.43% during the forecast period.
 |
To learn more about this report, request a free sample copy
Several breakthrough innovations in the pharmaceutical industry have led to the development of novel drug therapies that treat a broad range of diseases. Peptide receptor radionuclide therapy (PRRT) is among the next generation drug-based therapies that have been developed for targeting oncological disorders and rare disorders. It is a form of molecular therapy also known as radioisotope therapy that is used to treat specific cancer type such as neuroendocrine cancer. Peptide receptor radionuclide therapy contains targeted peptides or proteins labeled with radioactive material. These radiopeptides are injected directly into the bloodstream and travel to the site of tumor to bind neuroendocrine tumor cells - offering a personalized approach for the treatment of cancer.
One of the advantages of using peptide receptor radionuclide therapy is that they are selective in nature, possess the ability to reach targeted site and damage cancerous cells with minimal radiation exposure. This has increased the global demand for their use as cancer therapeutic. Owing to its structural integrity and target-specific mechanism of action, peptide receptor radionuclide therapy emerged as a potential alternative to the monoclonal antibody drug conjugates for the treatment of patients with oncological disorders. It is worth highlighting here that presently Novartis is leading the peptide receptor radionuclide therapy market with two marketed therapies - namely Lutathera and Pluvicto.
There have been extensive research going on in the broader field of radiopharmaceuticals, of which PRRT is a sub-segment. In addition to development of new drugs, the research has also been focused on development of combinations / expanding the indications. It is important to highlight here that in May 2024, the FDA has approved Lutathera® for the treatment of patients (12-17 years of age) suffering from somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Notably, Lutathera® become the first of its kind PRRT therapy to treat gastroenteropancreatic neuroendocrine tumors. The ongoing research synergies and collaborative initiatives between industrial players, healthcare providers and academic institutions are accelerating the development of advanced therapies, which is expected to drive the peptide receptor radionuclide therapy market during the forecast period.
The market report covers comprehensive analysis of various companies that are actively developing PRRT, along with the analysis of the market across different segments, as defined in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | 2035 | |
| Market Size 2035 | USD 30.1 billion | |
| CAGR | ~27.43% | |
| Type of Isotope |
|
|
| Type of Disease Indication |
|
|
| Type of Distribution Channels |
|
|
| Key Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the primary objectives of this peptide receptor radionuclide therapy market report was to estimate the current market size, value, trends, opportunities and future growth potential during the projected period. Based on multiple parameters, like adoption trends, evolutions, research and validation, we have provided an informed estimate on the market evolution during the forecast period till 2035.
The market report also highlight the likely distribution of the current and future opportunity for the market leaders active across various segments such as type of isotope (beta emitters and alpha emitters), type of disease indication (prostate cancer, gastroenteropancreatic-neuroendocrine tumors and other disease indications), distribution channel ((hospital pharmacies, retail pharmacies and online pharmacies), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of isotope, the peptide receptor radionuclide therapy market is segmented into beta emitters and alpha emitters. According to our projection, beta emitters, specifically Lutetium or Lu-177 accounts for 100% share of the market by revenue in 2024. Both the FDA approved PRRT drugs Lutathera and Pluvicto contain Lu-177 as the radioisotope. Beta emitters have shown higher efficacy in the treatment of neuroendocrine tumors particularly in patients who develop resistance against conventional therapies. These Lu-177 labelled peptide binds to the specific somatostatin receptors present on the tumor cells to induce tumor regression. This target specific approach enhances the efficacy of treatment and improves patient outcomes. A few other beta emitters such as Yttrium-90 have been used for therapeutic purpose in conjugation with an antibody.
In addition to beta emitters, more recently an alpha emitter based PRRT received Breakthrough Therapy Designation from the FDA. The drug AlphaMedixTM (212Pb-DOTAMTATE) is in phase II clinical trials for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Under development by RadioMedix and Orano Med, it is the first alpha emitter based PRRT.
The global peptide receptor radionuclide therapy market is segmented into prostate cancer and gastrointestinal-neuroendocrine tumors. In terms of disease indication, currently prostate cancer accounts for the highest share (65.6%) of the market driven by the increasing adoption of Pluvicto across the globe. The drug has seen strong market growth since its launch, achieving blockbuster status in 2024. Currently the drug is approved for post-taxane setting and has been filed for approval in pre-taxane setting in the US. Approval for this setting is expected in Q1 2025 and will increase the number of eligible patients for the drug. Additionally, a number of other submissions are expected for the drug in China and Japan by year end 2024. These factors together will continue to drive the growth of PRRT market for prostate cancer.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is the second largest segment in 2024, where Lutathera has been approved for both adult and pediatric population. The approval in pediatric patients was received from the FDA in April 2024. With the anticipated approval of targeted alpha therapy for this same indication, and the growing demand for tailored PRRT therapies for the treatment of patients, the market will witness strong growth over the forecast period.
Based on the type of distribution channel, the peptide receptor radionuclide therapy market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Among these, hospital pharmacies holds the highest substantial share within the peptide receptor radionuclide therapy market. This highest share is due to the fact that PRRT therapy is generally administered in the hospitals. It is important to highlight here that PRRT therapies has radioactive materials which require highly skilled personnel or nuclear pharmacist available in the hospitals. Owing to stringent handling requirements, hospital pharmacy segment will continue to grow at a higher CAGR during the forecast period.
The global peptide receptor radionuclide therapy market value is distributed into North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, rest of the world. Currently, North America occupies the largest share (35%) of the overall market. This highest growth share is due to the growing research initiatives and supportive framework for the approval of peptide receptor radionuclide therapies to target a wide range of disease indication. Additionally, the availability of advanced healthcare infrastructure and growing incidence of neuroendocrine tumors in this region has surged the demand for advanced therapies. Novartis reported strengthened its sales force in the US as well as increased the number of radiotherapy treatment sites in the region. The company alone claims to have ~530 treatment sites in the US.
However, the market for peptide receptor radionuclide therapy in Europe and Asia-Pacific is expected to grow at a substantial CAGR owing to the increasing healthcare expenditure, rising awareness about neuroendocrine tumors and improved healthcare facilities. Furthermore, the ongoing strategic initiatives by industrial leaders, research organizations and stakeholders has further fueled the market growth in this region.
Currently, the PRRT market landscape features the presence of several small, mid-sized and large companies. The key players engaged in the industry are currently investigating the therapy for treatment of oncological disorder. Several clinical trials have been conducted on peptide receptor radionuclide since 2018, indicating the enormous efforts by industrialist engaged in the industry.
Novartis’ Lutathera was the first PRRT to receive FDA approval in 2018, with the latest approval for treatment of GEP-NETs in pediatric population in April 2024. Pluvicto, the second PRRT, received approval from the FDA and EMA to treat patients with progressive PSMA-positive metastatic castration-resistant prostate cancer who have already taken other anticancer treatments in March and December 2022, respectively. In FY 2023, Novartis recorded sales of USD 980 million for Pluvicto and USD 605 million for Lutathera .
With positive outcomes, PRRT therapy has catered significant attention of the researchers to develop novel radiolabel peptide-based therapies to treat a broad range of cancer. In order to expand research on PRRT therapy, In March 2023, Novartis also forged a collaboration agreement with Bicycle Therapeutics to develop Bicycle radio-conjugates using bicycle peptides.
The rising prevalence of cancer across the globe has fueled the demand for next generation therapies to target cancer cells. According to the National Institute of Health, in 2024, over 2,001,140 new cases of cancer has been reported and around 611,720 deaths occurred due to cancer only in United States. In order to mitigate the growing risk of cancer, several pharmaceutical companies have increased their research and development efforts for creating next generation therapies such as peptide receptor radionuclide therapy.
Continuous research on advanced radioligands and finding innovative delivery methods to improve efficacy and safety have become a key driver of peptide receptor radioligand therapy market. Further, increasing adoption of PRRT by healthcare experts for the treatment of cancer patient has surged the demand for these target-based therapies.
The high cost associated with PRRT procedures including cost of radioligands remain as a significant barrier for healthcare system and patients. It is estimated that the cost of peptide receptor radionucleotide therapy is around USD 51,300 per cycle. The high cost associated with PRRT therapy may limit its adoption rate. Further, exposure to high radiation can have deteriorating effect on patients and may lead to off-target effects. Therefore, peptide receptor radionuclide therapy developers have to ensure radiation safety for both healthcare providers and patients, demanding rigorous training and protocols.
The inconsistent availability of radioligands can cause delay in the treatment of patients. In addition, navigating complex regulatory guidelines provided by various regulatory agencies across different regions can slow down the expansion of peptide receptor radionuclide ligand market. It is important to highlight here that the radiolabeled compounds specifically in PRRT therapies are relatively have short half-life, which limit its time for radiolabeling and patient administration. Owing to the short half-life, it create challenges in transporting peptide receptor radionucleotide therapies to distant location. Hence, logistical challenges associated with the transportation of PRRT therapy has created difficulty in the expanding the availability.
Peptide receptor radionuclide therapy emerge as a potential solution for targeting cancerous cells particularly neuroendocrine tumors. Owing to its high target specificity, various next generation therapy developers enter into partnerships and collaboration to develop advance PRRT therapy candidates. For instance, In February 2024, Orano Med and Radiomex received the FDA Breakthrough Therapy Designation for its AlphaMedix™ to treat gastroenteropancreatic neuroendocrine tumors. Phase II trial has been conducted for the evaluation of effectiveness and safety of the therapy on patients with somatostatin receptor-expressing neuroendocrine tumors. Moreover, in May 2023, Bayer and Bicycle Therapeutics entered into collaboration for the development of peptide receptor radioconjugates targeting cancer.
Driven by the successful trials and therapies receiving breakthrough therapy designation approval from the FDA, big pharma players has shown keen interest in peptide receptor radionuclide therapy, which is anticipated to grow market during the forecast period.
The global market for peptide receptor radionuclide therapy is expected to grow from USD 2.7 billion to USD 30.1 billion by 2035. Notably, North America currently holds the highest share of the market driven by the increasing demand for advanced therapeutic drugs for the treatment of oncological disorders. It will continue to be the case over the forecast period. Top industrial players such as Novartis AG and ITM Solucin are taking strategic initiatives to support the development of PRRT therapies. The successful approval from the FDA of PRRT is catering attention of the industrial leaders to support innovations in this industry. Driven by the ongoing efforts, the market is expected to grow at a CAGR of more than 27.43% during the forecast period.
Examples of key players engaged in the market of peptide receptors radionuclide therapy (which have also been captured in this report, arranged in alphabetical order) include Advanced Accelerator Applications (a Novartis company), Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Cellectar Biosciences, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Shenzhen Ascentawits Pharmaceuticals, Sirnaomics, Silence Therapeutics, and Suzhou Ribo Life Science. This market report includes an easily searchable excel database of all the peptide receptors nuclide therapy developers worldwide.
Several recent developments have taken place in the field of peptide receptor nuclide therapy, some of which have been outlined below.